Scarica l'app Stockscreener
2.73
1.09%
-0.03
Dopo l'orario di chiusura:
2.81
0.08
+2.93%
Precedente Chiudi:
$2.76
Aprire:
$2.71
Volume 24 ore:
19,162
Relative Volume:
0.08
Capitalizzazione di mercato:
$1.79M
Reddito:
-
Utile/perdita netta:
$-13.03M
Rapporto P/E:
-0.022
EPS:
-124.0371
Flusso di cassa netto:
$-6.53M
1 W Prestazione:
-5.21%
1M Prestazione:
-28.72%
6M Prestazione:
-66.95%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.70
$2.83
Intervallo di 1 settimana:
$2.63
$2.9453
Portata 52W:
$2.63
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
Nome
Decoy Therapeutics Inc
Settore
Industria
Telefono
346-772-0346
Indirizzo
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
2.73 | 1.81M | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-04-27 | Iniziato | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc Borsa (DCOY) Ultime notizie
Decoy Therapeutics CEO to present antiviral dru... - pluang.com
Decoy Therapeutics to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference - TMX Newsfile
Decoy Therapeutics Grants 3,900 Shares to Chief Business Officer Marschel Peter Klaus - Kalkine Media
Decoy Therapeutics Grants 2,000 Shares to Insider Gauthier Patricia G. at No Cost on August 31, 2026 - Kalkine Media
Director at Decoy Therapeutics (DCOY) awarded 2,000 restricted shares vesting in 2027 - Stock Titan
Decoy Therapeutics (DCOY) awards CEO 33,455 restricted shares - Stock Titan
Decoy Therapeutics (DCOY) awards CBO stock at $0 per share - Stock Titan
Decoy Therapeutics (DCOY) CFO granted multi-year stock award - Stock Titan
Chief scientist at Decoy Therapeutics (DCOY) gets 4,216-share stock grant - Stock Titan
Decoy Therapeutics (DCOY) director gets 3,000-share stock grant - Stock Titan
Director at Decoy Therapeutics (DCOY) granted 2,000 shares vesting in 2027 - Stock Titan
Director at Decoy Therapeutics (DCOY) gets 2,000-share grant vesting in 2027 - Stock Titan
Decoy Therapeutics (DCOY) awards 3,000 $0.00 shares to director - Stock Titan
Director at Decoy Therapeutics (DCOY) granted 2,000 restricted shares - Stock Titan
Moody Capital Solutions - TMX Newsfile
Decoy (DCOY) Results Check: EPS Prints Above Forecast in the Current Update; Post-Earnings: The Stock Records a 2.81% DecreaseRevenue Guidance Range - vinanet.vn
ARMISTICE CAPITAL, LLC Acquires Shares of Decoy Therapeutics Inc (DCOY) - GuruFocus
Decoy (DCOY) Latest Quarter: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: Shares Rise 0.29% in the Latest SessionRevenue Guidance Range - vinanet.vn
Decoy (DCOY) Trading Levels Update: Adds 1.14% to Close at $3.56 for the Current Session; Chart Reference - vinanet.vn
DCOY Q3 2024 Earnings: Narrower Loss of -136.8 per Share Delivers Positive SurpriseCash Flow Report - vinanet.vn
Decoy Therapeutics (DCOY) Advances 1.42% to $3.58, Holding Above SupportCTA Positioning - vinanet.vn
Armistice Capital (DCOY) discloses 65,503-share, 9.99% holding in Decoy Therapeutics - Stock Titan
DCOY Q2'26 Earnings: EPS estimate is (2.88) USD - TradingView
Decoy Therapeutics: Q2 Earnings Snapshot - Barchart.com
Decoy Therapeutics: Q2 Earnings Snapshot | Associated Press | syndication news - Enidnews.com
Decoy Therapeutics Inc. Q2 2026: Revenue $0.23M, Net loss $(2.37M), EPS $(4.46) — 10-Q Summary - TradingView
Decoy Therapeutics (DCOY) posts wider Q2 loss, flags going-concern and Nasdaq risks - Stock Titan
Decoy Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
DCOY Q3 2024 Earnings: Loss Narrows Sharply, Delivering 68.95% Positive EPS SurpriseGuidance Accuracy Score - vinanet.vn
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform - Morningstar
Decoy Therapeutics expands IP portfolio to 19 applications By Investing.com - Investing.com Nigeria
Decoy Therapeutics expands IP portfolio to 19 applications - Investing.com
Decoy Therapeutics (DCOY) Holds Firm Above $4 as Traders Eye Key Resistance at $4.32Wyckoff Accumulation - vinanet.vn
DCOY Q3 2024 Earnings: Loss Narrows Sharply, Beating Estimates by 68.95%Earnings Trend Analysis - vinanet.vn
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss of -136.8 per Share Highlights Cost DisciplineROA Comparison - vinanet.vn
DCOY Q3 2024 Earnings: Loss Narrower Than Expected as Cost Controls Take EffectShort-Term Outlook - vinanet.vn
Decoy Therapeutics (DCOY) Advances Research on D-MAV Candidates for Filoviruses - GuruFocus
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAVtm Platform into High Consequence Global Health Threats - Lelezard
Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus - TipRanks
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats - Morningstar
Decoy candidate shows activity against Ebola and Lassa in tests - Stock Titan
Decoy Therapeutics Inc. Revenue Breakdown – MUN:FP11 - TradingView
DCOY Q3 2024 Earnings: Narrower Loss Surprises; Pre-Revenue Stage Remains FocusEarnings Acceleration Picks - vinanet.vn
Decoy Therapeutics (DCOY) pursues warrant approvals and cuts authorized shares - Stock Titan
Decoy Therapeutics Inc. (NASDAQ: DCOY) Share Price, DCOY Stock News, DCOY Share Price & Updates - Kalkine
Decoy Therapeutics Inc. Revenue Breakdown – FWB:FP11 - TradingView
Decoy Therapeutics (DCOY) Rallies 1.42% as Shares Test Key Resistance at $5.24ETF Flow - dars.gov.et
Decoy Therapeutics Inc. SEC Filing (Jul 20, 2026) - Stock Titan
$5.86 | Decoy Therapeutics Inc. Common Stock (DCOY) Stock Price Today - Binance
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss Fails to Lift Sentiment as Stock Slides 10%Revenue Inflection Point - vinanet.vn
DCOY Q3 2024 Earnings: Smaller-than-Expected Loss Signals Cost Discipline Amid Clinical ProgressSaaS Earnings Trends - dars.gov.et
Decoy Therapeutics Inc Azioni (DCOY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):